WHO Sees 'Incredibly Low' COVID, Flu Vaccination Rates as Cases Surge

FILE PHOTO: A medical worker administers a dose of the "Cominarty" Pfizer-Bivalent coronavirus disease (COVID-19) vaccine to a patient at a vaccination center in Nice, France, December 7, 2022. REUTERS/Eric Gaillard/File Photo
FILE PHOTO: A medical worker administers a dose of the "Cominarty" Pfizer-Bivalent coronavirus disease (COVID-19) vaccine to a patient at a vaccination center in Nice, France, December 7, 2022. REUTERS/Eric Gaillard/File Photo
TT

WHO Sees 'Incredibly Low' COVID, Flu Vaccination Rates as Cases Surge

FILE PHOTO: A medical worker administers a dose of the "Cominarty" Pfizer-Bivalent coronavirus disease (COVID-19) vaccine to a patient at a vaccination center in Nice, France, December 7, 2022. REUTERS/Eric Gaillard/File Photo
FILE PHOTO: A medical worker administers a dose of the "Cominarty" Pfizer-Bivalent coronavirus disease (COVID-19) vaccine to a patient at a vaccination center in Nice, France, December 7, 2022. REUTERS/Eric Gaillard/File Photo

Low vaccination rates against the latest versions of COVID-19 and influenza are putting pressure on healthcare systems this winter, leading public health officials told Reuters.
In the United States, several European countries, and other parts of the world, there have been reports of rising hospitalizations linked to respiratory infections in recent weeks. Death rates have also ticked up among older adults in some regions, but far below the COVID pandemic peak.
Spain’s government has reinstated mask-wearing requirements at healthcare facilities, as have some US hospital networks.
“Too many people are in need of serious medical care for flu, for COVID, when we can prevent it,” said Maria Van Kerkhove, the World Health Organization’s interim director of epidemic and pandemic preparedness.
She cited “incredibly low” vaccination rates against flu and COVID in many countries this season, as the world tries to move past the pandemic and its restrictions.
Governments have struggled to communicate the risks still posed by COVID and the benefits of vaccination since a global public health emergency was declared over in May 2023, infectious disease experts and health officials said.
Only 19.4% of US adults have received this season’s COVID vaccine based on the US Centers for Disease Control (CDC) and Prevention’s National Immunization Survey, despite a recommendation that all adults get an updated shot to protect against serious illness.
That compares roughly with 17% of adults who got the bivalent booster in the 2022-2023 season, based on actual vaccine data reported to the CDC by states.
Nearly half of US adults over 18 got a flu shot this season (44.9%), roughly the same as last year (44%), according to the CDC.
“We don't think enough people have gotten the updated COVID vaccine,” CDC director Mandy Cohen said in an interview. “Folks still aren't understanding that COVID is still a more severe disease than flu.”
Flu represented 5.2% of US emergency visits compared with 3% for COVID in the week ended Dec. 30. Yet COVID accounted for 10.5 out of 100,000 hospitalizations in that time, compared with 6.1 per 100,000 for flu.
Most of the updated shots being used in the US and European Union are made by Pfizer with German partner BioNTech, or Moderna.
In Europe, flu is circulating at a higher rate than COVID, the European Centre for Disease Prevention and Control (ECDC) said. In total, 24% of a representative sample of tests came back positive in the last week of 2023, up from 19% a fortnight earlier.
The rates are in line with previous flu seasons, said ECDC’s respiratory virus expert Edoardo Colzani. But “now we have COVID-19 as a new, unwanted guest”, he said.
The ECDC did not have vaccination rates for the continent for flu or COVID, but Colzani said early data showed COVID vaccine uptake well below pandemic levels.
In Europe, the new COVID shots are recommended for high-risk groups only, such as seniors and the immunocompromised. Among these groups, the WHO says there should be 100% coverage.
COVID rates are also rising in the southern hemisphere during their summer, the WHO said, because it is not yet a seasonal virus.
Last month, 850,000 new COVID cases and 118,000 new hospitalizations were reported globally, a rise from November of 52% and 23%, respectively, according to WHO, which added that actual figures were likely higher.
The vaccines are still very effective at preventing serious illness, even if they do not block infection, experts said.



Japan's Space Agency Halts Epsilon S Rocket Engine Test after Fire

Smoke and fire is seen during a combustion test of an engine for a new small Japanese rocket Epsilon S at Tanegashima Space Center, Kagoshima prefecture, southern Japan, Tuesday, Nov. 26, 2024. (Kyodo News via AP)
Smoke and fire is seen during a combustion test of an engine for a new small Japanese rocket Epsilon S at Tanegashima Space Center, Kagoshima prefecture, southern Japan, Tuesday, Nov. 26, 2024. (Kyodo News via AP)
TT

Japan's Space Agency Halts Epsilon S Rocket Engine Test after Fire

Smoke and fire is seen during a combustion test of an engine for a new small Japanese rocket Epsilon S at Tanegashima Space Center, Kagoshima prefecture, southern Japan, Tuesday, Nov. 26, 2024. (Kyodo News via AP)
Smoke and fire is seen during a combustion test of an engine for a new small Japanese rocket Epsilon S at Tanegashima Space Center, Kagoshima prefecture, southern Japan, Tuesday, Nov. 26, 2024. (Kyodo News via AP)

Japan's space agency aborted an engine test for the Epsilon S rocket on Tuesday following a fire at the test site, a failure that could push the rocket's debut launch beyond the March-end target and cause further delays in the national space program.
An explosion could be heard and a blaze could be seen shortly after the ground combustion test started at the Tanegashima Space Center in southwestern Japan, according to footage from public broadcaster NHK.
The Japan Aerospace Exploration Agency (JAXA) said the engine test encountered a "combustion abnormality" 49 seconds after the ignition. It said there was no indication of injury or damage to the outside facility, Reuters reported.
"JAXA will conduct a thorough investigation into the cause of the problem and consider countermeasures," Chief Cabinet Secretary Yoshimasa Hayashi said at a regular press briefing.
Hayashi, the top government spokesperson, said rocket development is "extremely important" to ensure the autonomy of Japan's space program.
JAXA partnered with the aerospace unit of heavy machinery maker IHI to develop Epsilon S, the next generation in the Epsilon solid-fuel small rocket series. Shares in IHI were down as much as 6% in Tokyo trade. An IHI Aerospace spokesperson said the company is investigating the cause.
Epsilon S's debut flight was slated by the end of the fiscal year through March 31 depending on the success of Tuesday's engine test.
The test was conducted after previous failures triggered months of investigation that have delayed space missions and satellite launch plans.
In July last year, an Epsilon S engine test failed due to thermal damage to its ignition systems. That followed a launch failure in 2022.
JAXA's larger flagship rocket H3, built by Mitsubishi Heavy Industries, failed at its first launch last year but has succeeded in three flights this year, launching Japanese satellites and winning orders including from French satellite operator Eutelsat.
The H3 and Epsilon S are central to JAXA's ambition to build cost-competitive rockets amid the rise of American commercial launch providers such as market leader SpaceX and small rocket maker Rocket Lab.
In the private sector, IHI-backed Space One is set to attempt the second launch of its Kairos small rocket on Dec. 14 after the first flight exploded in March. It aims to become the first Japanese business to put a satellite in orbit.